A Phase 4 interventional study of Lifitegrast 5% Ophthalmic Solution in Dry Eye, sponsored by Bucci Laser Vision Institute. Withdrawn at 1 site in United States. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-07-27.
Sponsored by Bucci Laser Vision Institute · Phase 4, Interventional, and Treatment
To determine if the use of Xiidra® reduces ocular surface inflammation in preoperative and postoperative cataract patients.
Single-center, prospective, randomized, investigator-initiated study
250 cataract patients, aged 60 or older, will be tested for ocular surface inflammation with the InflammaDry® immunoassay
Patients with bilateral positive MMP-9 will be randomized into a group treated with Xiidra two weeks preoperatively and six weeks postoperatively or a group not treated with Xiidra
The investigator hypothesizes that treatment with Xiidra prior to routine cataract surgery will significantly improve the quality of keratometry readings and BCVA.
1,325 studies on the registry are indexed under Dry Eye Syndromes; 193 are open to participants now.
Browse Dry Eye Syndromes studies →Bucci Laser Vision Institute is the lead sponsor of 7 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
One drop of Lifitegrast Ophthalmic Solution 5% will be instilled into each eye twice daily (approximately 12 hours apart) using a single-use conainer.
Drug: Lifitegrast 5% Ophthalmic Solution
No treatment
BID OU
Compare the conversion rates of bilateral positive MMP-9 to negative in pre-cataract and post-cataract patients receiving treatment with Xiidra versus no Xiidra
Compare the conversion rates of bilateral positive MMP-9 to negative in pre-cataract and post-cataract patients receiving treatment with Xiidra versus no Xiidra
Time frame: 12 weeks
This study is withdrawn, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lifitegrast
Bucci Laser Vision Institute